The ideal joint replacement for CMC thumb arthritis.
ZEPART® is an advanced, anatomically optimized thumb implant for effective CMC osteoarthritis treatment.
ZEPART® Thumb Implant
Without a suitable joint replacement technology, surgeons are reduced to compromising treatment options for painful thumb CMC joint damaged by osteoarthritis. Our revolutionary implant meets the surgeon’s need for a stable, functional, adaptable thumb CMC joint replacement. Implementation of the ZEPART implant has the potential to address pain management for 200,000+ patients with this condition and restore quality of life.
The device shown is currently under development and has not yet received FDA clearance or approval. It is not available for sale in the United States.
Our Team
Rick Thomson
President and CEO
Nathan T. Morrell, MD, FAOA
Chief Medical Officer
Dimitri Madden
Chief Operating Officer
Ethan Darwin
Chief R&D Officer
Developed by Sandia Medical Technologies in Albuquerque, New Mexico.
Our all-star team is the emerging R&D leader for orthopedic surgery and related fields.
